Drug,Chemical Structure,Adverse Effect / Toxicity,Species,Dose,Dose Type,Route,Source,Source Link,Year,no_stereoisomer
Abemaciclib,CCN1CCN(CC1)CC1=CC=C(NC2=NC=C(F)C(=N2)C2=CC3=C(N=C(C)N3C(C)C)C(F)=C2)N=C1,Hepatotoxicity,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 208716/S-000 Part 09, page:15 PDF 678k",https://www.pharmapendium.com/browse/fda/Abemaciclib/a50315d3a726a8049e1d15f32cd253cf?reference=15,2017.0,CCN1CCN(CC1)CC1=CC=C(NC2=NC=C(F)C(=N2)C2=CC3=C(N=C(C)N3C(C)C)C(F)=C2)N=C1
Abiraterone Acetate,[H][C@@]12CC=C3C[C@H](CC[C@]3(C)[C@@]1([H])CC[C@]1(C)C(=CC[C@@]21[H])C1=CN=CC=C1)OC(C)=O,Hepatotoxicity,Human,-3.0,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/755312/2012; EMA/CHMP/755312/2012, page:38 PDF 1099k",https://www.pharmapendium.com/browse/ema/Abiraterone Acetate/ae6301d3961125608b3085a6feca6f2b?reference=38,2012.0,[H][C]12CC=C3C[CH](CC[C]3(C)[C]1([H])CC[C]1(C)C(=CC[C]21[H])C1=CN=CC=C1)OC(C)=O
Acalabrutinib,CC#CC(=O)N1CCC[C@H]1C1=NC(C2=CC=C(C=C2)C(=O)NC2=NC=CC=C2)=C2N1C=CN=C2N,Hepatotoxicity,Human,-2.0,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/CHMP/458179/2020; EMEA/H/C/005299/0000, page:142 PDF 6861k",https://www.pharmapendium.com/browse/ema/Acalabrutinib/7556c0cd9112408ddad445104df64083?reference=142,2020.0,CC#CC(=O)N1CCC[CH]1C1=NC(C2=CC=C(C=C2)C(=O)NC2=NC=CC=C2)=C2N1C=CN=C2N
Aceclofenac,OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,Hepatotoxicity,Human,-2.3010299956639813,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Aceclofenac225   ---   JOURNAL:Journal of Therapeutics and Clinical Risk Management   PAGES:225   VOLUME:3,,2007.0,OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
Acetaminophen,CC(=O)NC1=CC=C(O)C=C1,Hepatotoxicity,Human,-0.6020599913279624,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 022450/S-000 Part 02, page:17 PDF 945k",https://www.pharmapendium.com/browse/fda/Acetaminophen/3ab04f7a30d200f175f38314ad42ec5f?reference=17,2009.0,CC(=O)NC1=CC=C(O)C=C1
Acitretin,COC1=CC(C)=C(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)C(C)=C1C,Hepatotoxicity,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 019821, page:16 PDF 633k",https://www.pharmapendium.com/browse/fda/Acitretin/e52afb1fe8baa8e5ab992ef5ebed3ba5?reference=16,1994.0,COC1=CC(C)=C(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)C(C)=C1C
Agomelatine,COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1,Hepatotoxicity,Human,-1.6989700043360187,Repeated,Oral,"EMA approval document: Other Information from EMA EMA/740413/2013; EMEA/H/C/000916/PSUV/0017, page:2 PDF 46k",https://www.pharmapendium.com/browse/ema/Agomelatine/28e1d134bae50a9de79e259a2140c188?reference=2,2013.0,COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1
Alectinib Hydrochloride,CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C2=O)C2=C(N1)C=C(C=C2)C#N,Hepatotoxicity,Human,-2.7781512503836434,Repeated,Oral,"EMA approval document: ANNEX I, page:5 PDF 559k",https://www.pharmapendium.com/browse/ema/Alectinib Hydrochloride/c2ffb37bb4eeb11ca5e0a8ff296b9e86?reference=5,2020.0,CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C2=O)C2=C(N1)C=C(C=C2)C#N
Alosetron Hydrochloride,CN1C2=C(C(=O)N(CC2)CC2=C(C)NC=N2)C2=C1C=CC=C2,Hepatotoxicity,Human,-0.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021107/S-000 Part 09, page:13 PDF 694k",https://www.pharmapendium.com/browse/fda/Alosetron Hydrochloride/3660ebbe68e238ea21b2ccbe02a90b27?reference=13,1999.0,CN1C2=C(C(=O)N(CC2)CC2=C(C)NC=N2)C2=C1C=CC=C2
Ambrisentan,COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1,Hepatotoxicity,Human,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 022081/S-017 Part 05, page:50 PDF 6131k",https://www.pharmapendium.com/browse/fda/Ambrisentan/7eb36e2aef104a107f4e978fef0262de?reference=50,2011.0,COC([CH](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1
Aminoglutethimide,CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1,Hepatotoxicity,Human,-3.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 018202/S-014 Part 01, page:42 PDF 4351k",https://www.pharmapendium.com/browse/fda/Aminoglutethimide/261e6bcd70ef7293ed647d32e5e8ca20?reference=42,1979.0,CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1
Amiodarone Hydrochloride,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,Hepatotoxicity,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Approval Package 018972/S-014 Part 12, page:14 PDF 5420k",https://www.pharmapendium.com/browse/fda/Amiodarone Hydrochloride/4458ab986d830273f3d667d2639687ad?reference=14,1983.0,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1
Amlexanox,CC(C)C1=CC=C2OC3=NC(N)=C(C=C3C(=O)C2=C1)C(O)=O,Hepatotoxicity,Human,-0.3010299956639812,Repeated,Buccal,"FDA approval package document: Statistical Review 021727/S-000 Part 01, page:63 PDF 4968k",https://www.pharmapendium.com/browse/fda/Amlexanox/db5082887041e58329be6e73e96e7072?reference=63,2004.0,CC(C)C1=CC=C2OC3=NC(N)=C(C=C3C(=O)C2=C1)C(O)=O
Amoxicillin,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=C(O)C=C3)C(=O)N2[C@H]1C(O)=O,Hepatotoxicity,Human,-1.0791812460476249,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 050542/S-017; 050754/S-002; 050760/S-001; 050761/S-001, page:4 PDF 275k",https://www.pharmapendium.com/browse/fda/Amoxicillin/079f6473e812ed6a6222837d00e49d6e?reference=4,1999.0,CC1(C)S[CH]2[CH](NC(=O)[CH](N)C3=CC=C(O)C=C3)C(=O)N2[CH]1C(O)=O
Amphotericin B Liposome,C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@H]([C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@H](C)[C@@H](O)[C@H]1C)O2)C(O)=O,Hepatotoxicity,Human,-0.7781512503836436,Repeated,Intravenous,"FDA approval package document: Approval Package 050740/S-000, page:30 PDF 2697k",https://www.pharmapendium.com/browse/fda/Amphotericin B Liposome/09e8340a323dd2df58991540712bd514?reference=30,1997.0,C[CH]1OC(=O)C[CH](O)C[CH](O)CC[CH](O)[CH](O)C[CH](O)C[C]2(O)C[CH](O)[CH]([CH](C[CH](O[CH]3O[CH](C)[CH](O)[CH](N)[CH]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[CH](C)[CH](O)[CH]1C)O2)C(O)=O
Amprenavir,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,Hepatotoxicity,Human,-2.7781512503836434,Repeated,Oral,"EMA approval document: Procedural Steps, page:2 PDF 312k",https://www.pharmapendium.com/browse/ema/Amprenavir/a740ba3a0ea8e892593849e72a477102?reference=2,2009.0,CC(C)CN(C[CH](O)[CH](CC1=CC=CC=C1)NC(=O)O[CH]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1
Anidulafungin,CCCCCOC1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@@H](C)O,Hepatotoxicity,Human,-2.3010299956639813,Repeated,Intravenous,"FDA approval package document: Administrative documents 021948/S-000; 021632/S-000 Part 02, page:58 PDF 5379k",https://www.pharmapendium.com/browse/fda/Anidulafungin/c1e1c39739c62e30182703efe49d8286?reference=58,2005.0,CCCCCOC1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)N[CH]1C[CH](O)[CH](O)NC(=O)[CH]2[CH](O)[CH](C)CN2C(=O)[CH](NC(=O)[CH](NC(=O)[CH]2C[CH](O)CN2C(=O)[CH](NC1=O)[CH](C)O)[CH](O)[CH](O)C1=CC=C(O)C=C1)[CH](C)O
Apixaban,COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O,Hepatotoxicity,Human,-1.3010299956639813,Repeated,Oral,"EMA approval document: Assessment Report EMA/478338/2014; EMEA/H/C/002148/II/0014/G, page:91 PDF 2588k",https://www.pharmapendium.com/browse/ema/Apixaban/63204c7b176325279d63eef03f2d71ff?reference=91,2014.0,COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O
Arsenic Trioxide,O1[As]2O[As]1O2,Hepatotoxicity,Human,-1.1760912590556813,Repeated,Intravenous,"EMA approval document: ANNEX I, page:12 PDF 411k",https://www.pharmapendium.com/browse/ema/Arsenic Trioxide/1cdb91cd2ee9855cd123db7cda786a5d?reference=12,2020.0,O1[As]2O[As]1O2
Ataluren,OC(=O)C1=CC(=CC=C1)C1=NOC(=N1)C1=CC=CC=C1F,Hepatotoxicity,Human,-1.9030899869919435,Repeated,Oral,"EMA approval document: Assessment Report EMA/369266/2014; EMEA/H/C/002720, page:59 PDF 2832k",https://www.pharmapendium.com/browse/ema/Ataluren/4667dc0a327a57ad371e8811e3e74790?reference=59,2014.0,OC(=O)C1=CC(=CC=C1)C1=NOC(=N1)C1=CC=CC=C1F
Axitinib,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=NC=CC=C3)=C2)C=CC=C1,Hepatotoxicity,Human,-1.6020599913279623,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/453325/2012; EMEA/H/C/002406, page:73 PDF 1208k",https://www.pharmapendium.com/browse/ema/Axitinib/755c1be86b9ebb59766d67a496ec4500?reference=73,2012.0,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=NC=CC=C3)=C2)C=CC=C1
Balsalazide Disodium,OC1=CC=C(C=C1C([O-])=O)\N=N\C1=CC=C(C=C1)C(=O)NCCC([O-])=O,Hepatotoxicity,Human,-4.8750612633917,Repeated,Oral,"FDA approval package document: Label 020610/S-014, page:8 PDF 337k",https://www.pharmapendium.com/browse/fda/Balsalazide Disodium/84390a507bff32ec4c79256e84a73323?reference=8,2006.0,OC1=CC=C(C=C1C([O-])=O)\N=N\C1=CC=C(C=C1)C(=O)NCCC([O-])=O
Baricitinib,CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1,Hepatotoxicity,Human,-0.6020599913279624,Repeated,Oral,"EMA approval document: Assessment Report EMA/13493/2017; EMEA/H/C/004085/0000, page:123 PDF 2321k",https://www.pharmapendium.com/browse/ema/Baricitinib/0eb0578cd6751827e2647b4b84079d9f?reference=123,2016.0,CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
Binimetinib,CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C=C12)C(=O)NOCCO,Hepatotoxicity,Human,-1.6532125137753437,Repeated,Oral,"FDA approval package document: Approval Package 210498/S-000 Part 07, page:54 PDF 1296k",https://www.pharmapendium.com/browse/fda/Binimetinib/13a3940b1535a31fdb34095e0508a305?reference=54,2018.0,CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C=C12)C(=O)NOCCO
Bosutinib Monohydrate,COC1=C(Cl)C=C(Cl)C(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C1,Hepatotoxicity,Human,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 203341/S-000 Part 01, page:13 PDF 280k",https://www.pharmapendium.com/browse/fda/Bosutinib Monohydrate/65172101ea951be609b49591abfa58b6?reference=13,2011.0,COC1=C(Cl)C=C(Cl)C(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C1
Brigatinib,COC1=CC(=CC=C1NC1=NC(NC2=CC=CC=C2P(C)(C)=O)=C(Cl)C=N1)N1CCC(CC1)N1CCN(C)CC1,Hepatotoxicity,Human,-2.255272505103306,Repeated,Oral,"EMA approval document: Assessment Report EMA/140650/2020; EMEA/H/C/004248/II/0003, page:79 PDF 5666k",https://www.pharmapendium.com/browse/ema/Brigatinib/90bc8094fb1cd300b7ee28bf690bb302?reference=79,2020.0,COC1=CC(=CC=C1NC1=NC(NC2=CC=CC=C2P(C)(C)=O)=C(Cl)C=N1)N1CCC(CC1)N1CCN(C)CC1
Brivaracetam,CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1,Hepatotoxicity,Human,-0.6020599913279624,Repeated,Oral,"EMA approval document: Assessment Report EMA/472006/2018; EMEA/H/C/003898/II/0010/G, page:78 PDF 4461k",https://www.pharmapendium.com/browse/ema/Brivaracetam/81d520ae287ff454648ad5d430be7ede?reference=78,2018.0,CCC[CH]1CN([CH](CC)C(N)=O)C(=O)C1
Bromfenac Sodium,NC1=C(C=CC=C1CC([O-])=O)C(=O)C1=CC=C(Br)C=C1,Hepatotoxicity,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020535/S-000 Part 01, page:65 PDF 2621k",https://www.pharmapendium.com/browse/fda/Bromfenac Sodium/28f95038a4dde35baf3caef9ac420983?reference=65,1994.0,NC1=C(C=CC=C1CC([O-])=O)C(=O)C1=CC=C(Br)C=C1
Bupropion Hydrobromide,CC(NC(C)(C)C)C(=O)C1=CC=CC(Cl)=C1,Hepatotoxicity,Human,-2.5415792439465807,Repeated,Oral,"FDA approval package document: Label 022108/S-000, page:11 PDF 554k",https://www.pharmapendium.com/browse/fda/Bupropion Hydrobromide/fffb76494aafa1bef43f6bc4bf47db24?reference=11,2008.0,CC(NC(C)(C)C)C(=O)C1=CC=CC(Cl)=C1
Cabotegravir Sodium,[H][C@@]12CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C([O-])=C3C(=O)N1[C@@H](C)CO2,Hepatotoxicity,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Label 212887/S-001, page:17 PDF 709k",https://www.pharmapendium.com/browse/fda/Cabotegravir Sodium/460693f6c4dfc59f75b902ed8868b442?reference=17,2021.0,[H][C]12CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C([O-])=C3C(=O)N1[CH](C)CO2
Capmatinib Hydrochloride,CNC(=O)C1=CC=C(C=C1F)C1=NN2C(CC3=CC=C4N=CC=CC4=C3)=CN=C2N=C1,Hepatotoxicity,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Label 213591/S-001, page:4 PDF 603k",https://www.pharmapendium.com/browse/fda/Capmatinib Hydrochloride/d63f26f1797ace88ae86805f19ac5ed7?reference=4,2020.0,CNC(=O)C1=CC=C(C=C1F)C1=NN2C(CC3=CC=C4N=CC=CC4=C3)=CN=C2N=C1
Cefixime,NC1=NC(=CS1)\C(=N\OCC(O)=O)C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O,Hepatotoxicity,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202091/S-000, page:16 PDF 7528k",https://www.pharmapendium.com/browse/fda/Cefixime/a071a2ac64aa14e37189faad250655b4?reference=16,2011.0,NC1=NC(=CS1)\C(=N\OCC(O)=O)C(=O)N[CH]1[CH]2SCC(C=C)=C(N2C1=O)C(O)=O
Ceritinib,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1,Hepatotoxicity,Human,-2.8750612633917,Repeated,Oral,"EMA approval document: Assessment Report EMA/386332/2017; EMEA/H/C/003819/II/0012, page:90 PDF 6439k",https://www.pharmapendium.com/browse/ema/Ceritinib/0ce99201261a9d8e84a0cbcfc52ed714?reference=90,2017.0,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
Clomipramine Hydrochloride,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=C(Cl)C=C12,Hepatotoxicity,Human,-2.3979400086720375,Repeated,Oral,"FDA approval package document: Approval Package 019906/S-001, S-005, S-007, S-013, S-014, S-015, S-016 Part 02, page:24 PDF 6284k",https://www.pharmapendium.com/browse/fda/Clomipramine Hydrochloride/7f64ac728a5753933826e2fade0e8821?reference=24,1991.0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=C(Cl)C=C12
Clozapine,CN1CCN(CC1)C1=NC2=C(NC3=C1C=CC=C3)C=CC(Cl)=C2,Hepatotoxicity,Human,-2.9542425094393248,Repeated,Oral,"FDA approval package document: Label 203479/S-000, page:27 PDF 1267k",https://www.pharmapendium.com/browse/fda/Clozapine/107c277867a1040822f8ad90fa780b3d?reference=27,2013.0,CN1CCN(CC1)C1=NC2=C(NC3=C1C=CC=C3)C=CC(Cl)=C2
Colistimethate Sodium,CCC(C)CCCCC(=O)N[C@@H](CCNCS([O-])(=O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCNCS([O-])(=O)=O)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCNCS([O-])(=O)=O)NC(=O)[C@H](CCNCS([O-])(=O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCNCS([O-])(=O)=O)NC1=O)[C@@H](C)O,Hepatotoxicity,Human,-2.3979400086720375,Repeated,Inhalation,"EMA approval document: Assessment Report EMA/913717/2011; EMEA/H/C/001225, page:60 PDF 812k",https://www.pharmapendium.com/browse/ema/Colistimethate Sodium/4508c8c604e3d56c9dceedbba7fdbea1?reference=60,2011.0,CCC(C)CCCCC(=O)N[CH](CCNCS([O-])(=O)=O)C(=O)N[CH]([CH](C)O)C(=O)N[CH](CCNCS([O-])(=O)=O)C(=O)N[CH]1CCNC(=O)[CH](NC(=O)[CH](CCNCS([O-])(=O)=O)NC(=O)[CH](CCNCS([O-])(=O)=O)NC(=O)[CH](CC(C)C)NC(=O)[CH](CC(C)C)NC(=O)[CH](CCNCS([O-])(=O)=O)NC1=O)[CH](C)O
Conivaptan Hydrochloride,CC1=NC2=C(N1)C1=CC=CC=C1N(CC2)C(=O)C1=CC=C(NC(=O)C2=CC=CC=C2C2=CC=CC=C2)C=C1,Hepatotoxicity,Human,-1.9030899869919435,Repeated,Oral/intravenous,"FDA approval package document: Medical/Clinical Review 021697/S-000 Part 04, page:8 PDF 4481k",https://www.pharmapendium.com/browse/fda/Conivaptan Hydrochloride/ceccafb860ed08e83384df89ea48fc47?reference=8,2005.0,CC1=NC2=C(N1)C1=CC=CC=C1N(CC2)C(=O)C1=CC=C(NC(=O)C2=CC=CC=C2C2=CC=CC=C2)C=C1
Copanlisib Dihydrochloride,COC1=C2N=C(NC(=O)C3=CN=C(N)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1,Hepatotoxicity,Human,-1.4471580313422192,Repeated,Intravenous,"FDA approval package document: Approval Package 209936/S-000 Part 02, page:88 PDF 11850k",https://www.pharmapendium.com/browse/fda/Copanlisib Dihydrochloride/3a7a918dba0779ad831f58c4b35fbbbb?reference=88,2017.0,COC1=C2N=C(NC(=O)C3=CN=C(N)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1
Crizotinib,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,Hepatotoxicity,Human,-2.3979400086720375,Repeated,Oral,"EMA approval document: Other Information from EMA EMA/CHMP/453868/2012, page:1 PDF 47k",https://www.pharmapendium.com/browse/ema/Crizotinib/5166ca50205cca487f49f0b69faa9c8f?reference=1,2012.0,C[CH](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl
Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,Hepatotoxicity,Human,-1.1760912590556813,Repeated,Oral,"FDA approval package document: Approval Package 050573 Part 04, page:59 PDF 4409k",https://www.pharmapendium.com/browse/fda/Cyclosporine/6909d22756639b4844e9d9b997af0935?reference=59,1987.0,CC[CH]1NC(=O)[CH]([CH](O)[CH](C)C\C=C\C)N(C)C(=O)[CH](C(C)C)N(C)C(=O)[CH](CC(C)C)N(C)C(=O)[CH](CC(C)C)N(C)C(=O)[CH](C)NC(=O)[CH](C)NC(=O)[CH](CC(C)C)N(C)C(=O)[CH](NC(=O)[CH](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
Daclatasvir Dihydrochloride,COC(=O)NC(C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)C(NC(=O)OC)C(C)C,Hepatotoxicity,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 206843/S-000 Part 05, page:16 PDF 8280k",https://www.pharmapendium.com/browse/fda/Daclatasvir Dihydrochloride/4d4387a8439945ed1abcd63f38d98f7b?reference=16,2014.0,COC(=O)NC(C(C)C)C(=O)N1CCC[CH]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[CH]1CCCN1C(=O)C(NC(=O)OC)C(C)C
Dacomitinib,COC1=C(NC(=O)\C=C\CN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1,Hepatotoxicity,Human,-1.6532125137753437,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/201148/2019; EMEA/H/C/004779/0000, page:136 PDF 7228k",https://www.pharmapendium.com/browse/ema/Dacomitinib/579cd00a268ddcd1d8cd19badb26782b?reference=136,2019.0,COC1=C(NC(=O)\C=C\CN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Darunavir Ethanolate,[H][C@]12OCC[C@@]1([H])[C@H](CO2)OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1,Hepatotoxicity,Human,-2.7781512503836434,Repeated,Oral,"EMA approval document: Scientific Discussion, page:46 PDF 371k",https://www.pharmapendium.com/browse/ema/Darunavir Ethanolate/7b1fb045325097b8fbfdf15a806f3d44?reference=46,2006.0,[H][C]12OCC[C]1([H])[CH](CO2)OC(=O)N[CH](CC1=CC=CC=C1)[CH](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1
Dasatinib,CC1=NC(=CC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=N1)N1CCN(CCO)CC1,Hepatotoxicity,Human,-2.380211241711606,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021986/S-000; 022072/S-000 Part 01, page:94 PDF 4838k",https://www.pharmapendium.com/browse/fda/Dasatinib/3ea8354be86ba1946abb8a8c1060879e?reference=94,2006.0,CC1=NC(=CC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=N1)N1CCN(CCO)CC1
Deferasirox,OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O,Hepatotoxicity,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021882/S-015, page:53 PDF 19012k",https://www.pharmapendium.com/browse/fda/Deferasirox/1bc5e6d94c09702cdc491a7390df0456?reference=53,2013.0,OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O
Delamanid,C[C@]1(COC2=CC=C(C=C2)N2CCC(CC2)OC2=CC=C(OC(F)(F)F)C=C2)CN2C=C(N=C2O1)N(=O)=O,Hepatotoxicity,Human,-2.3010299956639813,Repeated,Oral,"EMA approval document: Assessment Report EMA/55567/2014; EMEA/H/C/002552, page:95 PDF 4324k",https://www.pharmapendium.com/browse/ema/Delamanid/e0682a9e8072d93e83504aa96dac2c8e?reference=95,2013.0,C[C]1(COC2=CC=C(C=C2)N2CCC(CC2)OC2=CC=C(OC(F)(F)F)C=C2)CN2C=C(N=C2O1)N(=O)=O
Diclofenac,OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,Hepatotoxicity,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Label 204592/S-000, page:6 PDF 635k",https://www.pharmapendium.com/browse/fda/Diclofenac/4aad834710ce57b1a00c9d4d2cc69313?reference=6,2013.0,OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
Diclofenac Potassium,[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,Hepatotoxicity,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Label 022202/S-000, page:6 PDF 1085k",https://www.pharmapendium.com/browse/fda/Diclofenac Potassium/753bf335ec07dc33069381fe02214df7?reference=6,2010.0,[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
Dolutegravir Sodium,[H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C([O-])=C3C(=O)N1[C@H](C)CCO2,Hepatotoxicity,Human,-2.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 204790 Part 04, page:28 PDF 7848k",https://www.pharmapendium.com/browse/fda/Dolutegravir Sodium/1ad0a2b9727ce58261902f144c3cb335?reference=28,2012.0,[H][C]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C([O-])=C3C(=O)N1[CH](C)CCO2
Doxycycline,[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O,Hepatotoxicity,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Label 050805/S-000, page:10 PDF 481k",https://www.pharmapendium.com/browse/fda/Doxycycline/42d5ff0efc953aa98ad84e11620d6031?reference=10,2006.0,[H][C]12[CH](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C]1(O)C(=O)C(C(N)=O)=C(O)[CH](N(C)C)[C]1([H])[CH]2O
Duloxetine Hydrochloride,CNCC[C@H](OC1=C2C=CC=CC2=CC=C1)C1=CC=CS1,Hepatotoxicity,Human,-2.0791812460476247,Repeated,Oral,"EMA approval document: Assessment Report EMA/285264/2012, page:45 PDF 2052k",https://www.pharmapendium.com/browse/ema/Duloxetine Hydrochloride/39ef776e021db2b54e949b9fd445a017?reference=45,2011.0,CNCC[CH](OC1=C2C=CC=CC2=CC=C1)C1=CC=CS1
Duvelisib,C[C@H](NC1=NC=NC2=C1N=CN2)C1=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1,Hepatotoxicity,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Approval Package 211155/S-000 Part 01, page:18 PDF 353k",https://www.pharmapendium.com/browse/fda/Duvelisib/cb7654ffc7f27bc13697850e11fc83eb?reference=18,2018.0,C[CH](NC1=NC=NC2=C1N=CN2)C1=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1
Efavirenz,FC(F)(F)[C@]1(OC(=O)NC2=CC=C(Cl)C=C12)C#CC1CC1,Hepatotoxicity,Human,-2.7781512503836434,Repeated,Oral,"EMA approval document: Assessment Report EMA/260283/2015; EMEA/H/C/000249/II/0126/G, page:54 PDF 2525k",https://www.pharmapendium.com/browse/ema/Efavirenz/c3645ccb445cfadf4554092a3dd66f73?reference=54,2015.0,FC(F)(F)[C]1(OC(=O)NC2=CC=C(Cl)C=C12)C#CC1CC1
Empagliflozin,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C(Cl)C=C1,Hepatotoxicity,Human,-1.3979400086720377,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/137741/2014; EMEA/H/C/002677/0000, page:94 PDF 1395k",https://www.pharmapendium.com/browse/ema/Empagliflozin/436354e1f4b6b84ebc2d059cab3caf56?reference=94,2014.0,OC[CH]1O[CH]([CH](O)[CH](O)[CH]1O)C1=CC(CC2=CC=C(O[CH]3CCOC3)C=C2)=C(Cl)C=C1
Emtricitabine,NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1,Hepatotoxicity,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021500/S-000 Part 02, page:20 PDF 1126k",https://www.pharmapendium.com/browse/fda/Emtricitabine/26e24691d2059f12dfd93a6e7d37ddc8?reference=20,2003.0,NC1=NC(=O)N(C=C1F)[CH]1CS[CH](CO)O1
Enfuvirtide,CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O,Hepatotoxicity,Human,-1.954242509439325,Repeated,Subcutaneous,"FDA approval package document: Medical/Clinical Review 021481/S-000 Part 03, page:26 PDF 1579k",https://www.pharmapendium.com/browse/fda/Enfuvirtide/9c859d46bfd410da3c7c3fe0f16ead14?reference=26,2003.0,CC[CH](C)[CH](NC(=O)[CH](CC(C)C)NC(=O)[CH](CO)NC(=O)[CH](CC1=CNC=N1)NC(=O)[CH](NC(=O)[CH](CC(C)C)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC1=CC=C(O)C=C1)NC(C)=O)[CH](C)O)[CH](C)CC)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CO)C(=O)N[CH](CCC(N)=O)C(=O)N[CH](CC(N)=O)C(=O)N[CH](CCC(N)=O)C(=O)N[CH](CCC(N)=O)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CCCCN)C(=O)N[CH](CC(N)=O)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CCC(N)=O)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CC(C)C)C(=O)N[CH](CC(C)C)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CC(C)C)C(=O)N[CH](CC(O)=O)C(=O)N[CH](CCCCN)C(=O)N[CH](CC1=CNC2=CC=CC=C12)C(=O)N[CH](C)C(=O)N[CH](CO)C(=O)N[CH](CC(C)C)C(=O)N[CH](CC1=CNC2=CC=CC=C12)C(=O)N[CH](CC(N)=O)C(=O)N[CH](CC1=CNC2=CC=CC=C12)C(=O)N[CH](CC1=CC=CC=C1)C(N)=O
Entrectinib,CN1CCN(CC1)C1=CC=C(C(=O)NC2=NNC3=C2C=C(CC2=CC(F)=CC(F)=C2)C=C3)C(NC2CCOCC2)=C1,Hepatotoxicity,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Approval Package 212725/S-000 Part 09, page:66 PDF 1542k",https://www.pharmapendium.com/browse/fda/Entrectinib/78fb3750df4bdbdc732d2025ec718ec7?reference=66,2019.0,CN1CCN(CC1)C1=CC=C(C(=O)NC2=NNC3=C2C=C(CC2=CC(F)=CC(F)=C2)C=C3)C(NC2CCOCC2)=C1
Erlotinib Hydrochloride,COCCOC1=CC2=NC=NC(NC3=CC=CC(=C3)C#C)=C2C=C1OCCOC,Hepatotoxicity,Human,-2.1760912590556813,Repeated,Oral,"EMA approval document: Assessment Report EMA/657134/2011; EMEA/H/C/000618/II/0020, page:38 PDF 1063k",https://www.pharmapendium.com/browse/ema/Erlotinib Hydrochloride/0710958c7d3dcd5c76c13e962d46333b?reference=38,2011.0,COCCOC1=CC2=NC=NC(NC3=CC=CC(=C3)C#C)=C2C=C1OCCOC
Etravirine,CC1=CC(=CC(C)=C1OC1=NC(NC2=CC=C(C=C2)C#N)=NC(N)=C1Br)C#N,Hepatotoxicity,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022187/S-000 Part 02, page:30 PDF 6254k",https://www.pharmapendium.com/browse/fda/Etravirine/23cba3104661ccebce18224813c53489?reference=30,2008.0,CC1=CC(=CC(C)=C1OC1=NC(NC2=CC=C(C=C2)C#N)=NC(N)=C1Br)C#N
Everolimus,CO[C@@H]1C[C@@H](CC[C@H]1OCCO)C[C@@H](C)[C@@H]1CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1)OC,Hepatotoxicity,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021560/S-000 Part 09, page:11 PDF 746k",https://www.pharmapendium.com/browse/fda/Everolimus/e2ef57f3b425158edc00b44ce0d6b22b?reference=11,2010.0,CO[CH]1C[CH](CC[CH]1OCCO)C[CH](C)[CH]1CC(=O)[CH](C)\C=C(C)\[CH](O)[CH](OC)C(=O)[CH](C)C[CH](C)\C=C\C=C\C=C(C)\[CH](C[CH]2CC[CH](C)[C](O)(O2)C(=O)C(=O)N2CCCC[CH]2C(=O)O1)OC
Fedratinib Hydrochloride,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC(=CC=C1)S(=O)(=O)NC(C)(C)C,Hepatotoxicity,Human,-2.6020599913279625,Repeated,Oral,"EMA approval document: Risk Management Plan Summary, page:3 PDF 148k",https://www.pharmapendium.com/browse/ema/Fedratinib Hydrochloride/061733f610ec77af319239ca83fb285a?reference=3,2021.0,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC(=CC=C1)S(=O)(=O)NC(C)(C)C
Felodipine,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC,Hepatotoxicity,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 019834/S-001, S-002, S-009 Part 12, page:4 PDF 8679k",https://www.pharmapendium.com/browse/fda/Felodipine/616fdcf13eea5049c9b29b37b2a513f4?reference=4,1997.0,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC
Fenofibrate,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1,Hepatotoxicity,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 019304 Part 02, page:49 PDF 5630k",https://www.pharmapendium.com/browse/fda/Fenofibrate/415bb5e46e4297edba28fcab10d7d046?reference=49,1993.0,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1
Fexofenadine Hydrochloride,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,Hepatotoxicity,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 201373/S-000 Part 11, page:29 PDF 876k",https://www.pharmapendium.com/browse/fda/Fexofenadine Hydrochloride/d7059e44b20a49f9940c212d18b49443?reference=29,2010.0,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
Fingolimod Hydrochloride,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1,Hepatotoxicity,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022527/S-000 Part 15, page:9 PDF 628k",https://www.pharmapendium.com/browse/fda/Fingolimod Hydrochloride/e915594d2e28cdace1210195661a719c?reference=9,2009.0,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1
Gatifloxacin,COC1=C(N2CCNC(C)C2)C(F)=CC2=C1N(C=C(C(O)=O)C2=O)C1CC1,Hepatotoxicity,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021062/S-011, S-017; 021404/S-000; 021405/S-000; 021061/S-010, S-016, page:35 PDF 3175k",https://www.pharmapendium.com/browse/fda/Gatifloxacin/204e7c7fb97980a0669b1760e9bcc83a?reference=35,2002.0,COC1=C(N2CCNC(C)C2)C(F)=CC2=C1N(C=C(C(O)=O)C2=O)C1CC1
Gefitinib,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC(Cl)=C(F)C=C1)=NC=N2,Hepatotoxicity,Human,-2.3979400086720375,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 206995/S-000 Part 02, page:1 PDF 12992k",https://www.pharmapendium.com/browse/fda/Gefitinib/e765d69482dd54d434698f4ede90d4af?reference=1,2015.0,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC(Cl)=C(F)C=C1)=NC=N2
Hetacillin,CC1(C)S[C@@H]2[C@H](N3C(=O)[C@H](NC3(C)C)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O,Hepatotoxicity,Human,-2.3979400086720375,Repeated,Oral,"FDA approval package document: Approval Package 050060, page:47 PDF 3891k",https://www.pharmapendium.com/browse/fda/Hetacillin/c6e53e404a31c2f806f183d66b8b5730?reference=47,1968.0,CC1(C)S[CH]2[CH](N3C(=O)[CH](NC3(C)C)C3=CC=CC=C3)C(=O)N2[CH]1C(O)=O
Hydroxyurea,NC(=O)NO,Hepatotoxicity,Human,-1.1760912590556813,Repeated,Oral,"FDA approval package document: Label 016295/S-039, page:11 PDF 501k",https://www.pharmapendium.com/browse/fda/Hydroxyurea/3d44936835b8473e1e680cbe6fd12fcb?reference=11,2005.0,NC(=O)NO
Ibrutinib,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,Hepatotoxicity,Human,-2.7481880270062002,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 210563/S-000, page:11 PDF 860k",https://www.pharmapendium.com/browse/fda/Ibrutinib/5e4a3f5cd04944779981cc771c971567?reference=11,2018.0,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[CH]1CCCN(C1)C(=O)C=C
Ibuprofen,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O,Hepatotoxicity,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 019012/S-016 Part 01, page:25 PDF 1240k",https://www.pharmapendium.com/browse/fda/Ibuprofen/168ea67898fa41752895e0b929f185d2?reference=25,1999.0,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
Idelalisib,CC[C@H](NC1=C2N=CNC2=NC=N1)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1,Hepatotoxicity,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Label 206545/S-000, page:3 PDF 1742k",https://www.pharmapendium.com/browse/fda/Idelalisib/554fd8297f7a7aeb285cc64d5c7e2b51?reference=3,2014.0,CC[CH](NC1=C2N=CNC2=NC=N1)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1
Irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1,Hepatotoxicity,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020757/S-000 Part 02, page:21 PDF 2473k",https://www.pharmapendium.com/browse/fda/Irbesartan/b5547d9a8065b8a16d2355fde6af56f2?reference=21,1997.0,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1
Isoniazid,NNC(=O)C1=CC=NC=C1,Hepatotoxicity,Human,-2.4771212547196626,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Ethionamide94904   ---   DOI:10.1517/14656560802694564   JOURNAL:Expert Opinion on Pharmacotherapy   PAGES:381   VOLUME:10,http://dx.doi.org/10.1517/14656560802694564,2009.0,NNC(=O)C1=CC=NC=C1
Isotretinoin,CC(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(C)=C\C(O)=O,Hepatotoxicity,Human,-0.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021951/S-000 Part 02, page:2 PDF 434k",https://www.pharmapendium.com/browse/fda/Isotretinoin/6844c8e23db76e65ca0ea5480aca2761?reference=2,2011.0,CC(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(C)=C\C(O)=O
Itraconazole,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,Hepatotoxicity,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Label 022484/S-000, page:6 PDF 424k",https://www.pharmapendium.com/browse/fda/Itraconazole/3cd8b4a77b6097a6d0ac27f3d8906782?reference=6,2010.0,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,Hepatotoxicity,Human,-3.0791812460476247,Repeated,Oral,"EMA approval document: ANNEX I, page:15 PDF 553k",https://www.pharmapendium.com/browse/ema/Ketoconazole/8d2315e4697688e9c94ee9b957e597c1?reference=15,2020.0,[H][C]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl
Ketoprofen,CC(C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1,Hepatotoxicity,Human,-2.0,Repeated,Oral,"FDA approval package document: Medical Officer Review 020429 Part 02, page:30 PDF 1711k",https://www.pharmapendium.com/browse/fda/Ketoprofen/294fff90244c022796a65f8836bc24b2?reference=30,1995.0,CC(C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1
Lacosamide,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1,Hepatotoxicity,Human,-2.7781512503836434,Repeated,Oral/intravenous,"FDA approval package document: Medical/Clinical Review 022253/S-000; 022254/S-000 Part 01, page:88 PDF 7378k",https://www.pharmapendium.com/browse/fda/Lacosamide/bd42e17957ba4fb8e413dec525a3b6de?reference=88,2008.0,COC[CH](NC(C)=O)C(=O)NCC1=CC=CC=C1
Lamivudine,NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1,Hepatotoxicity,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Medical Officer Review 020564, page:18 PDF 957k",https://www.pharmapendium.com/browse/fda/Lamivudine/833b22897d2ba0cd0d71a46580a23ec5?reference=18,1997.0,NC1=NC(=O)N(C=C1)[CH]1CS[CH](CO)O1
Lamotrigine,NC1=NC(N)=C(N=N1)C1=CC=CC(Cl)=C1Cl,Hepatotoxicity,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022509 Part 02, page:62 PDF 4325k",https://www.pharmapendium.com/browse/fda/Lamotrigine/d7ef1525b0b25b0f06cf2ca71ea0a14f?reference=62,2009.0,NC1=NC(N)=C(N=N1)C1=CC=CC(Cl)=C1Cl
Lansoprazole,CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1,Hepatotoxicity,Human,-1.954242509439325,Repeated,Oral,"FDA approval package document: Approval Package 078730/S-000 Part 02, page:8 PDF 368k",https://www.pharmapendium.com/browse/fda/Lansoprazole/c798ec4173255d287342e21e7070f635?reference=8,2010.0,CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1
Leflunomide,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F,Hepatotoxicity,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 020905/S-012 Part 01, page:23 PDF 7549k",https://www.pharmapendium.com/browse/fda/Leflunomide/fdf49b65034b357ebf5fc1e274ad855e?reference=23,2003.0,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F
Lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,Hepatotoxicity,Human,-1.3979400086720377,Repeated,Oral,"EMA approval document: ANNEX I, page:28 PDF 639k",https://www.pharmapendium.com/browse/ema/Lenalidomide/25cd756533c94cddbdd01735140f5be1?reference=28,2021.0,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Levocetirizine Dihydrochloride,OC(=O)COCCN1CCN(CC1)[C@H](C1=CC=CC=C1)C1=CC=C(Cl)C=C1,Hepatotoxicity,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 209089/S-000 Part 05, page:11 PDF 6557k",https://www.pharmapendium.com/browse/fda/Levocetirizine Dihydrochloride/948fdb30f4ff12481b10470f1e10197d?reference=11,2016.0,OC(=O)COCCN1CCN(CC1)[CH](C1=CC=CC=C1)C1=CC=C(Cl)C=C1
Levofloxacin,C[C@H]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O,Hepatotoxicity,Human,-2.8750612633917,Repeated,Oral,"FDA approval package document: Approval Package 020634/S-062, S-064; 020635/S-068, S-070; 021721/S-029, S-031, page:9 PDF 717k",https://www.pharmapendium.com/browse/fda/Levofloxacin/a832960109620e4dc9d39afea60f3ba7?reference=9,2011.0,C[CH]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
Loratadine,CCOC(=O)N1CC\C(CC1)=C1\C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2,Hepatotoxicity,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021375/S-000, page:44 PDF 3450k",https://www.pharmapendium.com/browse/fda/Loratadine/5fcaed66a34c7d2a7a80fecf3b42464d?reference=44,2002.0,CCOC(=O)N1CC\C(CC1)=C1\C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2
Lorlatinib,C[C@H]1OC2=CC(=CN=C2N)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=C1C=C(F)C=C2,Hepatotoxicity,Human,-2.0,Repeated,Oral,"FDA approval package document: Approval Package 210868/S-000 Part 09, page:57 PDF 1228k",https://www.pharmapendium.com/browse/fda/Lorlatinib/bd3ecb44dfc93ea65ade6b9e1d3ea355?reference=57,2018.0,C[CH]1OC2=CC(=CN=C2N)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=C1C=C(F)C=C2
Lubiprostone,[H][C@@]12CC(=O)[C@H](CCCCCCC(O)=O)[C@@]1([H])CC[C@@](O)(O2)C(F)(F)CCCC,Hepatotoxicity,Human,-1.380211241711606,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021908/S-016, page:90 PDF 16820k",https://www.pharmapendium.com/browse/fda/Lubiprostone/bbf1cd30cd52aead0a501a441d626912?reference=90,2018.0,[H][C]12CC(=O)[CH](CCCCCCC(O)=O)[C]1([H])CC[C](O)(O2)C(F)(F)CCCC
Maraviroc,[H][C@]12CC[C@]([H])(C[C@H](C1)N1C(C)=NN=C1C(C)C)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1,Hepatotoxicity,Human,-0.3010299956639812,Repeated,Oral,"EMA approval document: ANNEX I, page:5 PDF 775k",https://www.pharmapendium.com/browse/ema/Maraviroc/c4b566d7660838911f6e544f697ed177?reference=5,2020.0,[H][C]12CC[C]([H])(C[CH](C1)N1C(C)=NN=C1C(C)C)N2CC[CH](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1
Mefenamic Acid,CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1,Hepatotoxicity,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Approval Package 015034/S-034, page:11 PDF 929k",https://www.pharmapendium.com/browse/fda/Mefenamic Acid/5b6bfd3a3f1247bcc9254d5cf4068134?reference=11,2001.0,CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1
Meloxicam,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=CC=CC=C2S1(=O)=O,Hepatotoxicity,Human,-1.1760912590556813,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Aceclofenac225   ---   JOURNAL:Journal of Therapeutics and Clinical Risk Management   PAGES:225   VOLUME:3,,2007.0,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=CC=CC=C2S1(=O)=O
Melphalan Hydrochloride,N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O,Hepatotoxicity,Human,-1.1760912590556813,Repeated,Oral,"FDA approval package document: Approval Package 020207 Part 01, page:8 PDF 6524k",https://www.pharmapendium.com/browse/fda/Melphalan Hydrochloride/7cc60a80c649b63c1beb1aec984c4748?reference=8,1992.0,N[CH](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O
Mercaptopurine,S=C1NC=NC2=C1NC=N2,Hepatotoxicity,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Label 205919/S-000, page:3 PDF 1266k",https://www.pharmapendium.com/browse/fda/Mercaptopurine/c434c89bc8f0dc47ad8a93b7dfc72c7c?reference=3,2014.0,S=C1NC=NC2=C1NC=N2
Mesalamine,NC1=CC(C(O)=O)=C(O)C=C1,Hepatotoxicity,Human,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021252/S-000, page:29 PDF 886k",https://www.pharmapendium.com/browse/fda/Mesalamine/e57781584a161c76b39eaed350704075?reference=29,2001.0,NC1=CC(C(O)=O)=C(O)C=C1
Methylnaltrexone Bromide,C[N+]1(CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35)CC1CC1,Hepatotoxicity,Human,-1.0791812460476249,Repeated,Subcutaneous,"FDA approval package document: Administrative documents 021964/S-000, page:27 PDF 5278k",https://www.pharmapendium.com/browse/fda/Methylnaltrexone Bromide/b0ec6e429ed5f44a821ce0e9ca264d7c?reference=27,2008.0,C[N+]1(CC[C]23[CH]4OC5=C(O)C=CC(C[CH]1[C]2(O)CCC4=O)=C35)CC1CC1
Metoclopramide Hydrochloride,CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC,Hepatotoxicity,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Approval Package 078374/S-004, page:7 PDF 2645k",https://www.pharmapendium.com/browse/fda/Metoclopramide Hydrochloride/aa1e26cbb7b8ced7839b65e6b49f70a5?reference=7,2011.0,CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
Micafungin Sodium,[H][C@@]12C[C@@H](O)CN1C(=O)[C@@H](NC(=O)[C@H](C[C@@H](O)[C@@H](O)NC(=O)[C@]1([H])[C@@H](O)[C@@H](C)CN1C(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@H](O)[C@@H](O)C1=CC=C(O)C(OS([O-])(=O)=O)=C1)[C@H](O)CC(N)=O)NC(=O)C1=CC=C(C=C1)C1=NOC(=C1)C1=CC=C(OCCCCC)C=C1)[C@@H](C)O,Hepatotoxicity,Human,-2.1760912590556813,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 021754/S-000 Part 09, page:13 PDF 2226k",https://www.pharmapendium.com/browse/fda/Micafungin Sodium/d7ed237c9121b50d5a603746d4aa5f00?reference=13,2005.0,[H][C]12C[CH](O)CN1C(=O)[CH](NC(=O)[CH](C[CH](O)[CH](O)NC(=O)[C]1([H])[CH](O)[CH](C)CN1C(=O)[CH](NC(=O)[CH](NC2=O)[CH](O)[CH](O)C1=CC=C(O)C(OS([O-])(=O)=O)=C1)[CH](O)CC(N)=O)NC(=O)C1=CC=C(C=C1)C1=NOC(=C1)C1=CC=C(OCCCCC)C=C1)[CH](C)O
Miltefosine,CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C,Hepatotoxicity,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 204684/S-000 Part 03, page:123 PDF 1277k",https://www.pharmapendium.com/browse/fda/Miltefosine/aa4c69df27167c6277bcff2425b32b45?reference=123,2014.0,CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C
Minocycline Hydrochloride,[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2,Hepatotoxicity,Human,-0.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 201922/S-000 Part 04, page:3 PDF 1074k",https://www.pharmapendium.com/browse/fda/Minocycline Hydrochloride/2e0ad4e438b1aac52e2264799b6780d5?reference=3,2011.0,[H][C]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C]1(O)C(=O)C(C(N)=O)=C(O)[CH](N(C)C)[C]1([H])C2
Mirabegron,NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1,Hepatotoxicity,Human,-2.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202611/S-000 Part 01, page:17 PDF 356k",https://www.pharmapendium.com/browse/fda/Mirabegron/c47b4c34b8d499536bf18e6a77827e3e?reference=17,2012.0,NC1=NC(CC(=O)NC2=CC=C(CCNC[CH](O)C3=CC=CC=C3)C=C2)=CS1
Mitotane,ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=C(Cl)C=CC=C1,Hepatotoxicity,Human,-3.7781512503836434,Repeated,Oral,"EMA approval document: ANNEX I, page:4 PDF 425k",https://www.pharmapendium.com/browse/ema/Mitotane/a7a1adb13e3e762744b74fe4e101a823?reference=4,2020.0,ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=C(Cl)C=CC=C1
Nedocromil Sodium,CCCC1=C2OC(=CC(=O)C2=CC2=C1N(CC)C(=CC2=O)C([O-])=O)C([O-])=O,Hepatotoxicity,Human,-1.146128035678238,Repeated,Inhalation,"FDA approval package document: Approval Package 019660/S-003, S-010, S-015 Part 11, page:48 PDF 4368k",https://www.pharmapendium.com/browse/fda/Nedocromil Sodium/a232a17314fcd369588e235050bf00a3?reference=48,1993.0,CCCC1=C2OC(=CC(=O)C2=CC2=C1N(CC)C(=CC2=O)C([O-])=O)C([O-])=O
Nevirapine,CC1=CC=NC2=C1NC(=O)C1=C(N=CC=C1)N2C1CC1,Hepatotoxicity,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Label 201152/S-000, page:6 PDF 507k",https://www.pharmapendium.com/browse/fda/Nevirapine/18b79028e6ff80260708a5a806a0b4ce?reference=6,2011.0,CC1=CC=NC2=C1NC(=O)C1=C(N=CC=C1)N2C1CC1
Nilotinib Hydrochloride Monohydrate,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CC=CN=C3)=C(C)C=C2)=C1)C(F)(F)F,Hepatotoxicity,Human,-2.9030899869919438,Repeated,Oral,"EMA approval document: Assessment Report EMA/313746/2017; EMEA/H/C/000798/II/0084/G, page:58 PDF 2138k",https://www.pharmapendium.com/browse/ema/Nilotinib Hydrochloride Monohydrate/d01e77935612f8a2f5c9961a577b6a3b?reference=58,2017.0,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CC=CN=C3)=C(C)C=C2)=C1)C(F)(F)F
Nitric Oxide,[N]=O,Hepatotoxicity,Human,-1.3010299956639813,Repeated,Inhalation,"FDA approval package document: Medical/Clinical Review 020845 Part 03, page:21 PDF 3173k",https://www.pharmapendium.com/browse/fda/Nitric Oxide/0111a8354b24d9bcb931fedb9f23043a?reference=21,1997.0,[N]=O
Omeprazole Magnesium,COC1=CC=C2[N-]C(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C,Hepatotoxicity,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021229/S-000, page:9 PDF 20401k",https://www.pharmapendium.com/browse/fda/Omeprazole Magnesium/42ffe48b5d32d8a231f5c085c007aa78?reference=9,2003.0,COC1=CC=C2[N-]C(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C
Orlistat,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,Hepatotoxicity,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021887/S-000 Part 05, page:6 PDF 7300k",https://www.pharmapendium.com/browse/fda/Orlistat/56d8b756d89504eb6cbeda26cbc3c991?reference=6,2005.0,CCCCCCCCCCC[CH](C[CH]1OC(=O)[CH]1CCCCCC)OC(=O)[CH](CC(C)C)NC=O
Oxaprozin,OC(=O)CCC1=NC(C2=CC=CC=C2)=C(O1)C1=CC=CC=C1,Hepatotoxicity,Human,-3.0791812460476247,Repeated,Oral,"FDA approval package document: Approval Package 018841/S-003, S-001, S-002, S-004, S-005 Part 02, page:30 PDF 11237k",https://www.pharmapendium.com/browse/fda/Oxaprozin/a591ca196a9f82f4f0e7e4359c600b1f?reference=30,1992.0,OC(=O)CCC1=NC(C2=CC=CC=C2)=C(O1)C1=CC=CC=C1
Oxcarbazepine,NC(=O)N1C2=CC=CC=C2CC(=O)C2=CC=CC=C12,Hepatotoxicity,Human,-3.5563025007672873,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021014/S-000 Part 07, page:3 PDF 1179k",https://www.pharmapendium.com/browse/fda/Oxcarbazepine/f1f1062d405d96e1e8ea11e2da0c3a31?reference=3,1999.0,NC(=O)N1C2=CC=CC=C2CC(=O)C2=CC=CC=C12
Paroxetine Hydrochloride,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC=C2OCOC2=C1,Hepatotoxicity,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 020031/S-007, S-009 Part 01, page:55 PDF 6476k",https://www.pharmapendium.com/browse/fda/Paroxetine Hydrochloride/6854cd722a5523d7b251d686963e6b94?reference=55,1992.0,FC1=CC=C(C=C1)[CH]1CCNC[CH]1COC1=CC=C2OCOC2=C1
Pazopanib Hydrochloride,CN1N=C2C=C(C=CC2=C1C)N(C)C1=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=NC=C1,Hepatotoxicity,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Label 022465/S-000, page:6 PDF 485k",https://www.pharmapendium.com/browse/fda/Pazopanib Hydrochloride/aca42e3b2905412af9c3581cb0807583?reference=6,2009.0,CN1N=C2C=C(C=CC2=C1C)N(C)C1=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=NC=C1
Pexidartinib Hydrochloride,FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1,Hepatotoxicity,Human,-3.0,Repeated,Oral,"FDA approval package document: Approval Package 211810/S-000 Part 07, page:36 PDF 855k",https://www.pharmapendium.com/browse/fda/Pexidartinib Hydrochloride/b8014b9a95e2f8615062ebf1f04be996?reference=36,2019.0,FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1
Phenytoin,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1,Hepatotoxicity,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Approval Package 008762/S-039 Part 01, page:12 PDF 427k",https://www.pharmapendium.com/browse/fda/Phenytoin/f663eb919dfb8c88d5bfb73c9391cea1?reference=12,2011.0,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1
Piritrexim,COC1=CC=C(OC)C(CC2=C(C)C3=C(N)N=C(N)N=C3N=C2)=C1,Hepatotoxicity,Human,-0.6989700043360189,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Piritrexim-0250   ---   DOI:10.1038/bjc.1995.407   JOURNAL:British Journal of Cancer   PAGES:766   VOLUME:72,http://dx.doi.org/10.1038/bjc.1995.407,1995.0,COC1=CC=C(OC)C(CC2=C(C)C3=C(N)N=C(N)N=C3N=C2)=C1
Ponatinib Hydrochloride,CN1CCN(CC1)CC1=C(C=C(NC(=O)C2=CC(C#CC3=CN=C4C=CC=NN34)=C(C)C=C2)C=C1)C(F)(F)F,Hepatotoxicity,Human,-1.6532125137753437,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/220290/2013; EMEA/H/C/002695/0000, page:78 PDF 3061k",https://www.pharmapendium.com/browse/ema/Ponatinib Hydrochloride/fe3b348c74e83ea10cdb1f8b671495b8?reference=78,2013.0,CN1CCN(CC1)CC1=C(C=C(NC(=O)C2=CC(C#CC3=CN=C4C=CC=NN34)=C(C)C=C2)C=C1)C(F)(F)F
Posaconazole,CC[C@@H]([C@H](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@@](C2)(CN2C=NC=N2)C2=C(F)C=C(F)C=C2)C=C1,Hepatotoxicity,Human,-2.4771212547196626,Repeated,Oral,"EMA approval document: Assessment Report EMA/159150/2014; EMEA/H/C/000610/X/0028, page:58 PDF 3029k",https://www.pharmapendium.com/browse/ema/Posaconazole/24610bdc2cfadd322d44f3a151b8ea58?reference=58,2014.0,CC[CH]([CH](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[CH]2CO[C](C2)(CN2C=NC=N2)C2=C(F)C=C(F)C=C2)C=C1
Pralsetinib,CO[C@@]1(CC[C@@H](CC1)C1=NC(C)=CC(NC2=NNC(C)=C2)=N1)C(=O)N[C@@H](C)C1=CC=C(N=C1)N1C=C(F)C=N1,Hepatotoxicity,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 213721/S-000 Part 06, page:19 PDF 7982k",https://www.pharmapendium.com/browse/fda/Pralsetinib/26a0773d49143819947e790c5be9ae0d?reference=19,2020.0,CO[C]1(CC[CH](CC1)C1=NC(C)=CC(NC2=NNC(C)=C2)=N1)C(=O)N[CH](C)C1=CC=C(N=C1)N1C=C(F)C=N1
Ranitidine Hydrochloride,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C\N(=O)=O,Hepatotoxicity,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021698/S-000, page:109 PDF 7752k",https://www.pharmapendium.com/browse/fda/Ranitidine Hydrochloride/d649577b6b69cdfb36e83266f39471d9?reference=109,2004.0,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C\N(=O)=O
Regorafenib,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1,Hepatotoxicity,Human,-2.2041199826559246,Repeated,Oral,"FDA approval package document: Label 203085/S-000, page:2 PDF 841k",https://www.pharmapendium.com/browse/fda/Regorafenib/610db11b60f31926f279264da5b5c9bf?reference=2,2012.0,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
Remdesivir,CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)C1=CC=C2N1N=CN=C2N)OC1=CC=CC=C1,Hepatotoxicity,Human,-2.3010299956639813,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 214787/S-000 Part 03, page:45 PDF 1237k",https://www.pharmapendium.com/browse/fda/Remdesivir/27efae85ef2e8d3460cff7dde5014c8d?reference=45,2020.0,CCC(CC)COC(=O)[CH](C)N[P](=O)(OC[CH]1O[C](C#N)([CH](O)[CH]1O)C1=CC=C2N1N=CN=C2N)OC1=CC=CC=C1
Ribavirin,NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,Hepatotoxicity,Human,-0.3010299956639812,Repeated,Oral,"EMA approval document: ANNEX I, page:15 PDF 1151k",https://www.pharmapendium.com/browse/ema/Ribavirin/7ea0ca59f3b0605c1d1f91f28274f4c2?reference=15,2019.0,NC(=O)C1=NN(C=N1)[CH]1O[CH](CO)[CH](O)[CH]1O
Rilpivirine Hydrochloride,CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1,Hepatotoxicity,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202022, page:24 PDF 5039k",https://www.pharmapendium.com/browse/fda/Rilpivirine Hydrochloride/eb07d071fc7e8afce9c99ecef11cce7b?reference=24,2015.0,CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1
Riluzole,NC1=NC2=CC=C(OC(F)(F)F)C=C2S1,Hepatotoxicity,Human,-2.0,Repeated,Oral,"EMA approval document: Scientific Discussion, page:11 PDF 129k",https://www.pharmapendium.com/browse/ema/Riluzole/2fdd9339a096dccfb4bff884eb25d66e?reference=11,2004.0,NC1=NC2=CC=C(OC(F)(F)F)C=C2S1
Ritonavir,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,Hepatotoxicity,Human,-0.3010299956639812,Repeated,Oral,"EMA approval document: Procedural Steps EMA/185419/2021, page:29 PDF 423k",https://www.pharmapendium.com/browse/ema/Ritonavir/8c684a6035aac9aa304b6ad5952fe769?reference=29,2021.0,CC(C)[CH](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[CH](C[CH](O)[CH](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
Rivaroxaban,ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O,Hepatotoxicity,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022406/S-000 Part 15, page:12 PDF 3082k",https://www.pharmapendium.com/browse/fda/Rivaroxaban/f93854302776cab245cbb09dd26c441d?reference=12,2009.0,ClC1=CC=C(S1)C(=O)NC[CH]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O
Rofecoxib,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1,Hepatotoxicity,Human,-0.7781512503836436,Repeated,Oral,"FDA approval package document: Approval Package 021042/S-026; 021052/S-019 Part 02, page:24 PDF 7199k",https://www.pharmapendium.com/browse/fda/Rofecoxib/95ab35b3cb2960a0eb79298c99bcc499?reference=24,2003.0,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1
Selpercatinib,COC1=CC=C(CN2C3CC2CN(C3)C2=CC=C(C=N2)C2=CC(OCC(C)(C)O)=CN3N=CC(C#N)=C23)C=N1,Hepatotoxicity,Human,-2.2041199826559246,Repeated,Oral,"FDA approval package document: Approval Package 213246/S-000 Part 01, page:26 PDF 890k",https://www.pharmapendium.com/browse/fda/Selpercatinib/2c2ed46bdd69c1d7a4e7b128ef454a77?reference=26,2020.0,COC1=CC=C(CN2C3CC2CN(C3)C2=CC=C(C=N2)C2=CC(OCC(C)(C)O)=CN3N=CC(C#N)=C23)C=N1
Sirolimus,CO[C@@H]1C[C@@H](CC[C@H]1O)C[C@@H](C)[C@@H]1CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1)OC,Hepatotoxicity,Human,-0.3010299956639812,Repeated,Oral,"EMA approval document: Assessment Report EMA/493416/2018; EMEA/H/C/000273/II/0164, page:38 PDF 1955k",https://www.pharmapendium.com/browse/ema/Sirolimus/b2386abfadf57ba8715e15364baefdc4?reference=38,2018.0,CO[CH]1C[CH](CC[CH]1O)C[CH](C)[CH]1CC(=O)[CH](C)\C=C(C)\[CH](O)[CH](OC)C(=O)[CH](C)C[CH](C)\C=C\C=C\C=C(C)\[CH](C[CH]2CC[CH](C)[C](O)(O2)C(=O)C(=O)N2CCCC[CH]2C(=O)O1)OC
Sotorasib,CC(C)C1=NC=CC(C)=C1N1C(=O)N=C(N2CCN(C[C@@H]2C)C(=O)C=C)C2=CC(F)=C(N=C12)C1=C(O)C=CC=C1F,Hepatotoxicity,Human,-2.9822712330395684,Repeated,Oral,"FDA approval package document: Label 214665/S-001, page:4 PDF 805k",https://www.pharmapendium.com/browse/fda/Sotorasib/c5664fac0861ff234e58ece9a54e2869?reference=4,2021.0,CC(C)C1=NC=CC(C)=C1N1C(=O)N=C(N2CCN(C[CH]2C)C(=O)C=C)C2=CC(F)=C(N=C12)C1=C(O)C=CC=C1F
Strontium Ranelate,[O-]C(=O)CN(CC([O-])=O)C1=C(C#N)C(CC([O-])=O)=C(S1)C([O-])=O,Hepatotoxicity,Human,-3.3010299956639813,Repeated,Oral,"EMA approval document: Assessment Report EMA/PRAC/136656/2013, page:27 PDF 2812k",https://www.pharmapendium.com/browse/ema/Strontium Ranelate/ff0e59eece3e406389880f08e75d1029?reference=27,2013.0,[O-]C(=O)CN(CC([O-])=O)C1=C(C#N)C(CC([O-])=O)=C(S1)C([O-])=O
Sulfasalazine,OC(=O)C1=C(O)C=CC(=C1)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1,Hepatotoxicity,Human,-3.6020599913279625,Repeated,Oral,"FDA approval package document: Label 021243/S-000, page:9 PDF 874k",https://www.pharmapendium.com/browse/fda/Sulfasalazine/cf8a0c6ad016a2a507078cca2fee3df1?reference=9,2000.0,OC(=O)C1=C(O)C=CC(=C1)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1
Sunitinib,CCN(CC)CCNC(=O)C1=C(C)NC(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C,Hepatotoxicity,Human,-1.8750612633917,Repeated,Oral,"EMA approval document: ANNEX I, page:7 PDF 705k",https://www.pharmapendium.com/browse/ema/Sunitinib/95d35eea3df7c71029f241d18fa5927a?reference=7,2021.0,CCN(CC)CCNC(=O)C1=C(C)NC(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C
Tacrine Hydrochloride,NC1=C2C=CC=CC2=NC2=C1CCCC2,Hepatotoxicity,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Approval Package 020070/S-001, S-003, S-004, S-006 Part 04, page:9 PDF 8238k",https://www.pharmapendium.com/browse/fda/Tacrine Hydrochloride/51751d8e5678a771b82a2dfb6a882da6?reference=9,1993.0,NC1=C2C=CC=CC2=NC2=C1CCCC2
Tacrolimus,[H][C@]12O[C@](O)([C@H](C)C[C@@H]1OC)C(=O)C(=O)N1CCCC[C@H]1C(=O)O[C@@H]([C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)\C=C(C)\C[C@H](C)C[C@@H]2OC)C(\C)=C\[C@H]1CC[C@@H](O)[C@H](C1)OC,Hepatotoxicity,Human,-0.3010299956639812,Repeated,Oral,"FDA approval package document: Approval Package 065461/S-000 Part 01, page:12 PDF 725k",https://www.pharmapendium.com/browse/fda/Tacrolimus/4698c8cb5c55ba3c0318b8c572f08e3e?reference=12,2009.0,[H][C]12O[C](O)([CH](C)C[CH]1OC)C(=O)C(=O)N1CCCC[CH]1C(=O)O[CH]([CH](C)[CH](O)CC(=O)[CH](CC=C)\C=C(C)\C[CH](C)C[CH]2OC)C(\C)=C\[CH]1CC[CH](O)[CH](C1)OC
Teriflunomide,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F,Hepatotoxicity,Human,-1.146128035678238,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202992/S-000 Part 11, page:10 PDF 694k",https://www.pharmapendium.com/browse/fda/Teriflunomide/3644d3d04d1b175657ea26ae65c79637?reference=10,2012.0,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F
Teriparatide (rDNA Origin),CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O,Hepatotoxicity,Human,-1.3010299956639813,Repeated,Subcutaneous,"EMA approval document: Procedural Steps EMA/602683/2020, page:13 PDF 239k",https://www.pharmapendium.com/browse/ema/Teriparatide (rDNA Origin)/19dc3766ac6f82247be0a8ae079183d9?reference=13,2020.0,CC[CH](C)[CH](NC(=O)[CH](CCC(O)=O)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](N)CO)C(C)C)C(=O)N[CH](CCC(N)=O)C(=O)N[CH](CC(C)C)C(=O)N[CH](CCSC)C(=O)N[CH](CC1=CNC=N1)C(=O)N[CH](CC(N)=O)C(=O)N[CH](CC(C)C)C(=O)NCC(=O)N[CH](CCCCN)C(=O)N[CH](CC1=CNC=N1)C(=O)N[CH](CC(C)C)C(=O)N[CH](CC(N)=O)C(=O)N[CH](CO)C(=O)N[CH](CCSC)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CCCNC(N)=N)C(=O)N[CH](C(C)C)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CC1=CNC2=C1C=CC=C2)C(=O)N[CH](CC(C)C)C(=O)N[CH](CCCNC(N)=N)C(=O)N[CH](CCCCN)C(=O)N[CH](CCCCN)C(=O)N[CH](CC(C)C)C(=O)N[CH](CCC(N)=O)C(=O)N[CH](CC(O)=O)C(=O)N[CH](C(C)C)C(=O)N[CH](CC1=CNC=N1)C(=O)N[CH](CC(N)=O)C(=O)N[CH](CC1=CC=CC=C1)C(O)=O
Tipranavir,CCC[C@@]1(CCC2=CC=CC=C2)CC(O)=C([C@H](CC)C2=CC=CC(NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)=C2)C(=O)O1,Hepatotoxicity,Human,-2.6989700043360187,Repeated,Oral,"EMA approval document: ANNEX I, page:23 PDF 553k",https://www.pharmapendium.com/browse/ema/Tipranavir/8f4522d8a378b62a12c4ffb844a715fe?reference=23,2020.0,CCC[C]1(CCC2=CC=CC=C2)CC(O)=C([CH](CC)C2=CC=CC(NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)=C2)C(=O)O1
Tizanidine Hydrochloride,ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1,Hepatotoxicity,Human,-1.5563025007672873,Repeated,Oral,"FDA approval package document: Medical Officer Review 020397, page:12 PDF 1231k",https://www.pharmapendium.com/browse/fda/Tizanidine Hydrochloride/ba04919e66ed951ebe570134f802b17f?reference=12,1994.0,ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1
Tolvaptan,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=C1C=CC(Cl)=C2,Hepatotoxicity,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 204441/S-000 Part 05, page:15 PDF 600k",https://www.pharmapendium.com/browse/fda/Tolvaptan/26fba97841ed852caa0a9ddc3513d797?reference=15,2013.0,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=C1C=CC(Cl)=C2
Troleandomycin,CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1OC(C)=O)O[C@H]1[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(C)=O)N(C)C)[C@@H](C)C[C@@]2(CO2)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]1C,Hepatotoxicity,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Approval Package 050331, page:8 PDF 957k",https://www.pharmapendium.com/browse/fda/Troleandomycin/dce5622b265f7916994bc3b9c240a58f?reference=8,1959.0,CO[CH]1C[CH](O[CH](C)[CH]1OC(C)=O)O[CH]1[CH](C)[CH](O[CH]2O[CH](C)C[CH]([CH]2OC(C)=O)N(C)C)[CH](C)C[C]2(CO2)C(=O)[CH](C)[CH](OC(C)=O)[CH](C)[CH](C)OC(=O)[CH]1C
Tucatinib,CC1=CC(NC2=C3C=C(NC4=NC(C)(C)CO4)C=CC3=NC=N2)=CC=C1OC1=CC2=NC=NN2C=C1,Hepatotoxicity,Human,-2.4771212547196626,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/78409/2021; EMEA/H/C/005263/0000, page:132 PDF 7669k",https://www.pharmapendium.com/browse/ema/Tucatinib/9853a892aaf187403450ff694ca2cbcd?reference=132,2020.0,CC1=CC(NC2=C3C=C(NC4=NC(C)(C)CO4)C=CC3=NC=N2)=CC=C1OC1=CC2=NC=NN2C=C1
Ulipristal Acetate,[H][C@@]12CCC3=CC(=O)CCC3=C1[C@H](C[C@@]1(C)[C@@]2([H])CC[C@]1(OC(C)=O)C(C)=O)C1=CC=C(C=C1)N(C)C,Hepatotoxicity,Human,-0.6989700043360189,Repeated,Oral,"EMA approval document: Assessment Report EMA/524073/2020; EMEA/H/A-31/1496, page:31 PDF 617k",https://www.pharmapendium.com/browse/ema/Ulipristal Acetate/2d37b140ac61a0c85a7db660f18f2cdb?reference=31,2020.0,[H][C]12CCC3=CC(=O)CCC3=C1[CH](C[C]1(C)[C]2([H])CC[C]1(OC(C)=O)C(C)=O)C1=CC=C(C=C1)N(C)C
Valproic Acid,CCCC(CCC)C(O)=O,Hepatotoxicity,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Approval Package 018081/S-001, S-009, S-025; 018082/S-008; 018841/S-008; 005856/S-013; 006800/S-011; 007707/S-004; 008322/S-007 Part 02, page:34 PDF 5153k",https://www.pharmapendium.com/browse/fda/Valproic Acid/c45e2929cad56b2dac1b3a43f96fdf20?reference=34,1978.0,CCCC(CCC)C(O)=O
Vemurafenib,CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1,Hepatotoxicity,Human,-2.9822712330395684,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202429/S-000 Part 01, page:9 PDF 376k",https://www.pharmapendium.com/browse/fda/Vemurafenib/c613801a833bc7399850ae59137fa84d?reference=9,2011.0,CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1
Vigabatrin,NC(CCC(O)=O)C=C,Hepatotoxicity,Human,-3.7781512503836434,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020427/S-000 Part 06, page:53 PDF 6387k",https://www.pharmapendium.com/browse/fda/Vigabatrin/150f09a447bc03963ea33ba49100971a?reference=53,2009.0,NC(CCC(O)=O)C=C
Voriconazole,C[C@@H](C1=C(F)C=NC=N1)[C@](O)(CN1C=NC=N1)C1=CC=C(F)C=C1F,Hepatotoxicity,Human,-2.5440680443502757,Repeated,Oral,"EMA approval document: ANNEX I, page:6 PDF 517k",https://www.pharmapendium.com/browse/ema/Voriconazole/d9fc206768deb319740316a7dd18ee25?reference=6,2020.0,C[CH](C1=C(F)C=NC=N1)[C](O)(CN1C=NC=N1)C1=CC=C(F)C=C1F
Zaleplon,CCN(C(C)=O)C1=CC=CC(=C1)C1=CC=NC2=C(C=NN12)C#N,Hepatotoxicity,Human,-1.0,Repeated,Oral,"EMA approval document: ANNEX I, page:7 PDF 839k",https://www.pharmapendium.com/browse/ema/Zaleplon/3e0c835988bf7b6f2fd1508e419c1912?reference=7,2015.0,CCN(C(C)=O)C1=CC=CC(=C1)C1=CC=NC2=C(C=NN12)C#N
